Menu

Categories

Best Shopping Centers in Brazil

© 2012 BlogName - All rights reserved.

Firstyme WordPress Theme.
Designed by Charlie Asemota.

Talkspace Has Been Receiving Some Fantastic Reviews From Its Many Users:

July 6, 2019 - Author: steph

One thing that is certain about the revolutionary mental health counselling app Talkspace is the fact that its users really like it and they are not afraid to express their satisfaction in this revolutionary new service that is making mental health counselling more accessible and convenient than ever before. Reading through reviews that Talkspace users have left online will quickly show how Talkspace counsellors have a true ability at understanding how to help their patients to work through the struggles that they might be facing at the moment. It is not uncommon to find Talkspace users providing high levels of praise for their counsellors in this regard.

Check out opencounseling.com to learn more about Talkspace.

High levels of praise for the level of professionalism that Talkspace counsellors exhibit is one thing that users regularly comment on but another area is the fact that Talkspace users love how convenient the service is. It really does provide them with a level of access to counselling services that would have been unheard of just a decade before. This really is a huge part of the goal that the Talkspace founder had when the coming was started. It is all about providing new levels of access to the counselling that mental health patients need.

Talkspace is the service that has changed the concept of the way counselling services are delivered to patients in the area of mental health. The service is an app that can be accessed by way of text or video on any of today’s mobile and home-based devices. Talkspace users can then communicate with certified mental health counsellors in a convenient manner that allows them to receive the help that they need wherever they are. This service really is changing the game in a dramatic manner when it comes to how this important counselling service is delivered to today’s patients. Read: https://www.usatoday.com/story/tech/columnist/stevenpetrow/2017/01/24/text-based-therapy-not-ready-prime-time/96799556/

No Comments - Categories: App, Health, Medical, Mental Health, Technology, Therapeutics, Treatment

The Research And History Of Amicus Therapeutics

July 11, 2017 - Author: steph

Amicus Therapeutics is an American biopharmaceutical company located in Cranbury, New Jersey. In 2007 the company went public after a planned offering in 2006 followed by a withdrawal. The offering would have made AMTX the established symbol for trading. Amicus was funded by numerous capital firms including New Enterprise Associates, Radius Ventures and Canaan Partners.

Amicus Therapeutics focuses on rare and orphan diseases although their main objective is a disorder called lysosomal storage. The development of the company’s products is based on the Chaperone-Advanced Replacement Therapy also referred to as CHART. They have concentrated on developing therapies for enzyme replacement. Amicus’s reputation expanded in 2004 when their broadcast portfolio was noted in the pharmaceutical industry for small molecule pharmacological chaperones.

Amicus Therapeutics had no products marketed in 2014 and their most likely candidate was migalastat which uses the trade name of Galafold. The product is a treatment for Fabry disease with the goal of stabilizing endogenous mutant alpha-galactosidase. The company is also involved with JCR Pharmaceutical and GlaxoSmithKline in the investigation of coformulation with recombinant alpha-galactosidase. This partnership began in 2010 and continued until 2013.

Amicus Therapeutics expanded from their only site in New Jersey in 2008 to an additional research facility located in San Diego, California. By the end of 2009 the termination of a long collaboration with Shire caused financial setbacks. At this point in time private placements were used to finance their operations. This occurred with the use of proceeds secured with their first public offering, preferred stock and the agreement they had with Shire. The began restructuring at a corporate level to reduce their workforce by twenty percent.

Amicus Therapeutics received a United States grant in 2010. The $500,000 was received from the Michael J. Fox Foundation to support collaborative studies at UCLA with the David Geffen School of Medicine. An additional $210,300 grant was received in 2010 from the foundation for Alzheimer Drug Discovery. The grant supported their pre-clinical work and was a collaboration between Amicus and Mount Sinai’s Icahn School of Medicine. Amicus acquired the company Scioderm in September of 2015 for $947 million in stocks and cash.

 

 

No Comments - Categories: Therapeutics